{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:08:19Z","timestamp":1793236099040,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0250-9","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:39:55Z","timestamp":1457483995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":232,"title":["Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor"],"prefix":"10.1186","volume":"9","author":[{"given":"Jingjing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"issue":"12","key":"250_CR1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"1","key":"250_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-014-0099-8","volume":"8","author":"G Fan","year":"2015","unstructured":"Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8(1):1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"250_CR3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","volume":"7","author":"U Reusch","year":"2015","unstructured":"Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584\u2013604.","journal-title":"MAbs"},{"issue":"1","key":"250_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-014-0058-4","volume":"7","author":"T Suresh","year":"2014","unstructured":"Suresh T, Lee L, Joshi J, Barta S. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"250_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1470-2045(14)71183-0","volume":"16","author":"X Thomas","year":"2014","unstructured":"Thomas X. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol. 2014;16(1):6\u20137.","journal-title":"Lancet Oncol"},{"key":"250_CR6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"250_CR7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):104.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"250_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","volume":"8","author":"S Cang","year":"2015","unstructured":"Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8(1):129.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"250_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"250_CR10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-015-0165-x","volume":"8","author":"K Rai","year":"2015","unstructured":"Rai K. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015;8(1):85.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"250_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-3-4","volume":"3","author":"A Novero","year":"2014","unstructured":"Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Experimental Hematology & Oncology. 2014;3(1):1\u20137.","journal-title":"Experimental Hematology & Oncology"},{"issue":"6","key":"250_CR12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015;373(6):584\u20136.","journal-title":"N Engl J Med"},{"issue":"15","key":"250_CR13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015;372(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"250_CR14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.13278","volume":"170","author":"Y Cao","year":"2015","unstructured":"Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170(1):134\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"250_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"250_CR16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"19","key":"250_CR17","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","volume":"125","author":"JR Brown","year":"2015","unstructured":"Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125(19):2915\u201322.","journal-title":"Blood"},{"issue":"25","key":"250_CR18","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"15 Supplement","key":"250_CR19","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1158\/1538-7445.AM2015-2596","volume":"75","author":"T Covey","year":"2015","unstructured":"Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al. Abstract 2596: ACP-196: a novel covalent Bruton\u2019s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15 Supplement):2596.","journal-title":"Cancer Res"},{"issue":"19 Supplement","key":"250_CR20","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1538-7445.AM2014-1757","volume":"74","author":"A Vidal-Crespo","year":"2014","unstructured":"Vidal-Crespo A, Rodr\u00edguez V, Matas-C\u00e9spedes A, Campos E, L\u00f3pez-Guillermo A, Rou\u00e9 G, et al. Abstract 1757: the novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models. Cancer Res. 2014;74(19 Supplement):1757.","journal-title":"Cancer Res"},{"key":"250_CR21","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1158\/1538-7445.AM2015-2597","volume":"75","author":"L Na","year":"2015","unstructured":"Na L, Zhijian S, Ye L, Mingming G, Yilu Z, Dongping Z, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015;75:2597.","journal-title":"Cancer Res"},{"issue":"23","key":"250_CR22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","volume":"126","author":"C Tam","year":"2015","unstructured":"Tam C, Grigg AP, Opat S, Ku M, Gilbertson M, Anderson MA, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832.","journal-title":"Blood"},{"issue":"4","key":"250_CR23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, Rule SA, Dyer MJS, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411\u20139.","journal-title":"Blood"},{"issue":"4","key":"250_CR24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332.","journal-title":"N Engl J Med"},{"issue":"19 Supplement","key":"250_CR25","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1538-7445.AM2014-1744","volume":"74","author":"HL Gardner*","year":"2014","unstructured":"Gardner* HL, Harrington* BK, Izumi R, Hamdy A, Kaptein A, Lith BV, et al. Abstract 1744: ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. Cancer Res. 2014;74(19 Supplement):1744.","journal-title":"Cancer Res"},{"issue":"23","key":"250_CR26","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V126.23.2908.2908","volume":"126","author":"BK Harrington","year":"2015","unstructured":"Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, et al. ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.","journal-title":"Blood"},{"issue":"15 Supplement","key":"250_CR27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1538-7445.AM2015-408","volume":"75","author":"BJ Lannutti","year":"2015","unstructured":"Lannutti BJ, Gulrajani M, Krantz F, Bibikova E, Covey T, Jessen K, et al. Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer. Cancer Res. 2015;75(15 Supplement):408.","journal-title":"Cancer Res"},{"issue":"19 Supplement","key":"250_CR28","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/1538-7445.AM2014-2624","volume":"74","author":"CU Niemann","year":"2014","unstructured":"Niemann CU, Montraveta A, Herman SEM, Ingallinera T, Barf T, Colomer D, et al. Abstract 2624: the novel Bruton\u2019s tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model. Cancer Res. 2014;74(19 Supplement):2624.","journal-title":"Cancer Res"},{"issue":"23","key":"250_CR29","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood.V126.23.2920.2920","volume":"126","author":"SEM Herman","year":"2015","unstructured":"Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, et al. The Bruton tyrosine kinase (BTK) inhibitor ACP-196 demonstrates clinical activity in two mouse models of chronic lymphocytic leukemia. Blood. 2015;126(23):2920.","journal-title":"Blood"},{"issue":"12","key":"250_CR30","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","volume":"27","author":"SE Herman","year":"2013","unstructured":"Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311\u201321.","journal-title":"Leukemia"},{"issue":"12","key":"250_CR31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMe1400599","volume":"370","author":"KR Rai","year":"2014","unstructured":"Rai KR, Barrientos JC. Movement toward optimization of CLL therapy. N Engl J Med. 2014;370(12):1160\u20132.","journal-title":"N Engl J Med"},{"issue":"7","key":"250_CR32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Q Yang","year":"2015","unstructured":"Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21(7):1537\u201342.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"250_CR33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-015-0122-8","volume":"8","author":"C Iragavarapu","year":"2015","unstructured":"Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8(1):17.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"250_CR34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)\u2014a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78.","journal-title":"J Hematol Oncol"},{"key":"250_CR35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","volume":"4","author":"A Das","year":"2015","unstructured":"Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015;4:7.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"250_CR36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"23","key":"250_CR37","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood.V126.23.2763.2763","volume":"126","author":"X Zhao","year":"2015","unstructured":"Zhao X, Rajasekaran N, Reusch U, Weichel M, Ellwanger K, Marschner J-P, et al. In vitro and in vivo characterization of CD19\/CD3 Tandab AFM11 and CD19\/CD16A Tandab AFM12 targeting NHL. Blood. 2015;126(23):2763.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0250-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T21:46:02Z","timestamp":1600292762000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/9\/1\/21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0250-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]},"article-number":"21"}}